KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vertex Pharmaceuticals (VRTX) Total Liabilities (2016 - 2025)

Historic Total Liabilities for Vertex Pharmaceuticals (VRTX) over the last 17 years, with Q4 2025 value amounting to $7.0 billion.

  • Vertex Pharmaceuticals' Total Liabilities rose 1393.95% to $7.0 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $7.0 billion, marking a year-over-year increase of 1393.95%. This contributed to the annual value of $7.0 billion for FY2025, which is 1393.95% up from last year.
  • Vertex Pharmaceuticals' Total Liabilities amounted to $7.0 billion in Q4 2025, which was up 1393.95% from $7.5 billion recorded in Q3 2025.
  • In the past 5 years, Vertex Pharmaceuticals' Total Liabilities ranged from a high of $7.5 billion in Q3 2025 and a low of $3.0 billion during Q2 2021
  • For the 5-year period, Vertex Pharmaceuticals' Total Liabilities averaged around $4.9 billion, with its median value being $5.0 billion (2023).
  • Per our database at Business Quant, Vertex Pharmaceuticals' Total Liabilities crashed by 252.9% in 2021 and then soared by 4179.18% in 2023.
  • Over the past 5 years, Vertex Pharmaceuticals' Total Liabilities (Quarter) stood at $3.3 billion in 2021, then increased by 27.18% to $4.2 billion in 2022, then rose by 21.51% to $5.1 billion in 2023, then increased by 18.91% to $6.1 billion in 2024, then grew by 13.94% to $7.0 billion in 2025.
  • Its Total Liabilities was $7.0 billion in Q4 2025, compared to $7.5 billion in Q3 2025 and $6.9 billion in Q2 2025.